ALX
Alexander's, Inc.
$246.22
-3.82
(-1.53%)
Mkt Cap
1.26B
Volume
22,492
52W Range
201.28-260.84
Sector
Real Estate
Beta
0.77
EPS (TTM)
4.00
P/E Ratio
61.55
Revenue (TTM)
211.68M
Rev Growth (5Y)
+1.4%
EPS Growth (5Y)
-7.7%
AlphaVal · Fair Value
$230.74
Overvalued · Mild
6.7% above fair value
AlphaQuality · Grade
D
Real Estate Investment Trust
38.4 / 100 composite
Company Description
Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 213.18M | 226.37M | 224.96M | 205.81M | 206.15M | 199.14M | 226.35M | 232.82M | 230.57M | 226.94M | 207.91M | 200.81M |
| Net Income | 28.22M | 43.44M | 102.41M | 57.63M | 132.93M | 41.94M | 21.17M | 32.84M | 80.51M | 86.48M | 76.91M | 67.92M |
| EPS | 5.50 | 8.46 | 19.97 | 11.24 | 25.94 | 8.19 | 4.14 | 6.42 | 15.74 | 16.91 | 15.04 | 13.29 |
| Free Cash Flow | 73.44M | 54.11M | 109.11M | 102.55M | 118.47M | 78.07M | 126.07M | 69.57M | 119.99M | 115.31M | N/A | N/A |
| FCF / Share | 14.30 | 10.54 | 21.27 | 20.01 | 23.12 | 15.24 | 24.63 | 13.60 | 23.45 | 22.55 | N/A | N/A |
| Operating CF | 73.44M | 54.11M | 109.11M | 102.55M | 118.47M | 78.07M | 126.07M | 73.54M | 123.43M | 130.82M | N/A | N/A |
| Total Assets | 1.11B | 1.34B | 1.40B | 1.40B | 1.39B | 1.40B | 1.27B | 1.48B | 1.63B | 1.45B | N/A | N/A |
| Total Debt | 943.07M | 1.10B | 1.09B | 1.09B | 1.09B | 1.16B | 970.96M | 1.16B | 1.24B | 1.05B | N/A | N/A |
| Cash & Equiv | 128.17M | 338.53M | 531.86M | 194.93M | 463.54M | 428.71M | 298.06M | 283.06M | 307.54M | 288.93M | N/A | N/A |
| Book Value | 109.16M | 176.86M | 237.66M | 236.50M | 252.59M | 203.23M | 253.51M | 285.09M | 343.95M | 352.85M | N/A | N/A |
| Return on Equity | 0.26 | 0.25 | 0.43 | 0.24 | 0.53 | 0.21 | 0.08 | 0.12 | 0.23 | 0.25 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.41M | 53.26M | 53.42M | 51.59M | 54.91M | 55.91M | 55.67M | 53.39M | 61.40M | 62.94M | 55.41M | 53.67M |
| Net Income | 4.66M | 3.82M | 5.97M | 6.12M | 12.31M | 12.28M | 6.68M | 8.38M | 16.11M | 16.29M | 10.75M | 64.15M |
| EPS | 0.91 | 0.74 | 1.16 | 1.19 | 2.40 | 2.39 | 1.30 | 1.63 | 3.14 | 3.17 | 2.10 | 12.51 |
| Free Cash Flow | 6.82M | 23.42M | (9.27M) | 43.57M | 15.72M | 30.81M | (5.03M) | 11.50M | 16.82M | 44.74M | (1.54M) | 45.17M |
| FCF / Share | 1.33 | 4.56 | -1.80 | 8.48 | 3.06 | 6.00 | -0.98 | 2.24 | 3.28 | 8.72 | -0.30 | 8.81 |
| Operating CF | 6.82M | 23.42M | (9.27M) | 43.57M | 15.72M | 30.81M | (5.03M) | 11.50M | 16.82M | 44.74M | (1.54M) | 45.17M |
| Total Assets | 1.10B | 1.11B | 1.30B | 1.32B | 1.33B | 1.34B | 1.36B | 1.48B | 1.39B | 1.40B | 1.41B | 1.43B |
| Total Debt | 945.62M | 943.07M | 1.10B | 1.10B | 1.10B | 1.10B | 1.10B | 1.20B | 1.09B | 1.09B | 1.09B | 1.09B |
| Cash & Equiv | 76.24M | 128.17M | 286.14M | 313.04M | 319.90M | 338.53M | 354.82M | 410.95M | 526.34M | 531.86M | 507.92M | 531.33M |
| Book Value | 90.72M | 109.16M | 128.33M | 145.45M | 163.09M | 176.86M | 190.69M | 212.52M | 230.14M | 237.66M | 251.82M | 265.64M |
| Return on Equity | 0.05 | 0.04 | 0.05 | 0.04 | 0.08 | 0.07 | 0.04 | 0.04 | 0.07 | 0.07 | 0.04 | 0.24 |
ALX News
The Most Hated High Yields On Wall Street
First Look: Aramco profit jump, Nvidia-Corning deal, GM fined
ALX Oncology Q1 Earnings Call Highlights
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
Alexander's (ALX) Q1 FFO and Revenues Lag Estimates
A Look at Alexander's Inc (ALX) After 3.0% Decline -- GF Value $203.84 vs Price $244.34
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call